CellaVision
On track despite challenging conditions in the quarter
MAR
Organic sales growth:
Q3, 2022: -3% (52)
EBITDA margin:
Q3, 2022: 21% (32)
Summary, July 1-September 30, 2022
- Net sales increased by 7% to SEK 141 m (132).
- Sales decreased organically by 3% (52), currency effect 10%.
- EBITDA amounted to SEK 29 m (42).
- EBITDA margin amounted to 21% (32).
- Profit before tax amounted to SEK 13 m (33).
- Earnings per share before and after dilution increased to SEK 0.44 (1.09).
- Cash flow from operating activities increased to SEK 31 m (49).
Datum | 2022-10-26, kl 07:20 |
Källa | MFN |

Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet